

Limitations:

- Cannot be used if a patient has prior resistance to INSTIs or NNRTIs, excluding the K103N mutation in isolation
- Limited data on use during pregnancy or breast/chestfeeding; in individuals with prior virologic failure, and in individuals with gluteal implants or soft tissue fillers
- Does not treat HBV coinfection
- A 4-week oral lead-in of CAB and RPV may be used before the first injection to assess for unexpected reactions or allergies to CAB or RPV
- Requires oral medications as bridging therapy when injections are missed
- Medication storage requirements (2° C to 8° C [36° F to 46° F])
- Requires 6 to 12 in-person visits with a healthcare provider per year

Potential Risks:

- Injection site reactions and other adverse effects, including pyrexia
- Development of resistance if doses are missed outside the 7-day window period, given the long half-life ("tail") of CAB and RPV
- Improved patient satisfaction
- Monthly (every 4 weeks) or bimonthly (every 8 weeks) administration
- Directly observed
- Low rates of virologic failure (resistance can develop despite optimal adherence, but this is rare)
- Noninferior to oral ART
- Potential option for patients who have ongoing substance use, mental health concerns, neurocognitive disorders, disclosure concerns, or other challenges associated with adherence to oral ART, including difficulty swallowing pills
- Removes the daily reminder of HIV status that is associated with taking pills
- Safe and efficacious in patients with chronic renal disease or on intermittent hemodialysis

Benefits:

- Improved patient satisfaction
- Monthly (every 4 weeks) or bimonthly (every 8 weeks) administration
- Directly observed
- Low rates of virologic failure (resistance can develop despite optimal adherence, but this is rare)
- Noninferior to oral ART
- Potential option for patients who have ongoing substance use, mental health concerns, neurocognitive disorders, disclosure concerns, or other challenges associated with adherence to oral ART, including difficulty swallowing pills
- Removes the daily reminder of HIV status that is associated with taking pills
- Safe and efficacious in patients with chronic renal disease or on intermittent hemodialysis

BOX 1: Summary of Benefits, Risks, and Limitations of CAB/RPV LA

Laboratory Testing and Monitoring

- Clinicians should perform baseline and routine monitoring of patients receiving injectable ART according to the recommendations in the following NYSDOH AI guidelines (A3): Virologic and Immunologic Monitoring and Laboratory Monitoring for Adverse Effects of ART.

ALL RECOMMENDATIONS (continued from P.2)

Managing Missed or Delayed Injections

Planned: If a patient plans to miss or delay a scheduled injection by >7 days, oral therapy can be taken for up to 2 consecutive months (8 weeks). Alternatively, a patient's previous suppressive oral ART regimen may be considered as a bridge if it was well tolerated, with care to assess for potential drug-drug interactions with coadministered medications. Oral therapy should be started approximately 1 month (4 weeks) after the last monthly injection or 2 months (8 weeks) after the last bimonthly injection and continued until injections are resumed.

Unplanned, monthly (every 4 weeks) injection schedule: If a patient who is not taking oral bridging CAB/RPV misses a monthly injection by >7 days and will resume injectable therapy, restart injections as follows:

- If last injection was ≤2 months (≤8 weeks) prior, resume as soon as possible with a maintenance dose injection of CAB 400 mg (2 mL)/RPV 600 mg (2 mL) IM.
- If last injection was >2 months (>8 weeks) prior, resume as soon as possible with a high-dose injection of CAB 600 mg (3 mL)/RPV 900 mg (3 mL) IM once followed by monthly (every 4 weeks) maintenance dosing 400 mg (2 mL)/RPV 600 mg (2 mL) IM.

Unplanned, bimonthly (every 8 weeks) injection schedule: If a patient who is not taking oral bridging CAB/RPV misses an injection and will resume injectable therapy, restart injections as soon as possible: within 2 months (8 weeks) if the second initial injection was missed or within 3 months (12 weeks) if any other bimonthly maintenance injection was missed. If outside of those windows, a second dose should be administered 1 month (4 weeks) after reinitiation of injections, with subsequent return to bimonthly (every 8 weeks) dosing.

GOOD PRACTICE

- Follow up by phone within 1 week after initiation of oral therapy lead-in, if used, and within 3 days after a patient receives the initial loading dose of injectable ART to assess the patient's tolerance.

Abbreviations: ART, antiretroviral therapy; CAB, cabotegravir; CAB/RPV LA, injectable long-acting cabotegravir/rilpivirine; CVF, confirmed virologic failure; HBV, hepatitis B virus; IM, intramuscular; INSTI, integrase strand transfer inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; RAM, resistance-associated mutation; RPV, rilpivirine.

Administration

- CAB/RPV LA should be administered by a licensed and trained healthcare professional. (A*)
- To prepare and administer CAB/RPV LA, clinicians should follow the protocols detailed in Box 2 and in the medication package inserts. (A1)

Dosing Strategy and Managing Missed Injections

- If an oral lead-in is chosen to assess medication tolerability, the clinician should prescribe up to 4 weeks of oral CAB/RPV. (A3)
- Once a dosing schedule is decided upon, clinicians should administer CAB/RPV LA as detailed in Table 2 or Table 3; a bimonthly (every 8 weeks) dosing schedule is preferred. (A1)
- If a patient plans to miss or delay a monthly CAB/RPV LA injection by >7 days, the clinician should arrange for oral medication (CAB 30 mg and RPV 25 mg daily), or other active regimen to be available in advance in an adequate supply (up to 2 months/8 weeks) to cover the gap in injections.
- Clinicians should resume CAB/RPV LA in patients who miss injections as detailed in Managing Missed or Delayed Injections. (A3)

Discontinuing CAB/RPV LA

- Clinicians should discontinue CAB/RPV LA in patients with confirmed virologic failure (defined as 2 consecutive plasma HIV-1 RNA measurements ≥200 copies/mL) or evidence of INSTI or NNRTI RAMs, excluding the K103N mutation in isolation, on subsequent genotype testing. (A1)
- Clinicians should discontinue CAB/RPV LA in patients with evidence of INSTI mutation in isolation, on subsequent genotype testing. (A1)
- Clinicians should discontinue CAB/RPV LA in patients with evidence of INSTI mutation in isolation, on subsequent genotype testing. (A1)
- When extended or frequent gaps occur between injections, resulting in prolonged periods of subtherapeutic drug concentrations, the risk of drug resistance increases; to avoid this risk, clinicians should encourage patients to adhere to the injection schedule and should switch to oral therapy for patients who cannot maintain the injection schedule. (A3)
- If CAB/RPV LA is discontinued, the clinician should initiate a fully suppressive oral ART regimen no later than 1 month (4 weeks) following the final CAB/RPV LA monthly injection or 2 months (8 weeks) following final CAB/RPV LA bimonthly injection. (A2)

ALL RECOMMENDATIONS (continued from P.1)

HIV CLINICAL RESOURCE ■■■ ¼-FOLDED GUIDE

VISIT HIVGUIDELINES.ORG TO LEARN MORE OR VIEW COMPLETE GUIDE

USE OF INJECTABLE CAB/RPV LA AS REPLACEMENT ART

NYSDOH AIDS INSTITUTE HIV CLINICAL GUIDELINE JANUARY 2026

ALL RECOMMENDATIONS **P.1**

Benefits, Potential Risks, and Limitations of CAB/RPV LA

- Clinicians should offer CAB/RPV LA as replacement ART for adults (aged ≥18 years) with HIV who are virally suppressed (HIV RNA level <50 copies/mL) and prefer an alternative to daily oral therapy. (A1)
- For patients who are not virally suppressed and have ongoing adherence challenges with oral ART (even with support) or are mechanically unable to ingest oral ART, the clinician should engage the patient in shared decision-making and offer monthly CAB/RPV LA, if susceptible, coupled with intensified follow-up support. (A2) Once viral suppression is achieved and maintained, consider transition to every-8-weeks dosing. (A3)
- Before recommending a switch to CAB/RPV LA, clinicians should determine patients' HBV status (hepatitis B surface antigen, core antibody, surface antibody, and HBV DNA test if indicated); CAB/RPV LA should not be recommended for patients with active HBV coinfection without concurrent oral therapy for HBV. (A*)
- Clinicians should not recommend CAB/RPV LA in patients with known or suspected INSTI or NNRTI RAMs, excluding the K103N mutation in isolation, at baseline. (A1)
- Before recommending CAB/RPV LA, clinicians should review results of prior resistance testing and ART treatment history, including all reasons for ART modification. (A3)
- Clinicians should obtain proviral DNA genotypic resistance testing that includes both the reverse transcriptase and integrase genes before switching to CAB/RPV LA in any patient for whom historical resistance test results are not available or if sustained viral suppression is not documented. (A2)
- Clinicians should not recommend treatment with CAB/RPV LA for patients who are pregnant or breast/chestfeeding, because of limited safety and efficacy data. (A*)

Continued on next panel >

DOSING STRATEGIES

TABLE 2: Optional Lead-in, Initiation, and Maintenance for Monthly (every 4 weeks) CAB/RPV LA Dosing

Timing	Dosing and Administration	Comments
Week 0 (month 0)	CAB 30 mg/RPV 25 mg once daily by mouth with a meal for 4 weeks	Optional oral medication lead-in
Week 4 (month 1)	CAB 600 mg (3 mL)/RPV 900 mg (3 mL) IM injection	Initiation dose: Administer on last day of oral lead-in or prior suppressive ART regimen
Week 8 (month 2) and every 4 weeks (every 1 month) thereafter	CAB 400 mg (2 mL)/RPV 600 mg (2 mL) IM injection	Maintenance dose: Administer within 7 days before or after scheduled date (see Managing Missed or Delayed Injections)

TABLE 3: Optional Lead-in, Initiation, and Maintenance for Bimonthly (every 8 weeks) CAB/RPV LA Dosing

Timing	Dosing and Administration	Comments
Week 0 (month 0)	CAB 30 mg/RPV 25 mg once daily by mouth with a meal for 4 weeks	Optional oral medication lead-in
Week 4 (month 1)	CAB 600 mg (3 mL)/RPV 900 mg (3 mL) IM injection	Initiation dose: Administer on last day of oral lead-in or prior suppressive ART regimen
Week 8 (month 2)	CAB 600 mg (3 mL)/RPV 900 mg (3 mL) IM injection	Maintenance dose: Administer within 7 days before or after scheduled date (see Managing Missed or Delayed Injections)
Week 16 (month 4) and every 8 weeks (every 2 months) thereafter	CAB 600 mg (3 mL)/RPV 900 mg (3 mL) IM injection	Maintenance dose: Administer within 7 days before or after scheduled date (see Managing Missed or Delayed Injections)

TABLE 4: Advantages and Limitations of CAB/RPV LA Dosing Strategies

Advantage or Limitation	Monthly (every 4 weeks) Dosing	Bimonthly (every 8 weeks) Dosing
Required annual visits	12	6
Injection site pain [a]	Less	More
CVF despite on-time dosing [b]	Rare	Rare
Risk of CAB and/or RPV RAMs if CVF	Common	Common
Patient satisfaction	High	Preferred
Staffing, administration time, and cost	More	Less

Notes:

- In the ATLAS-2M trial, 3% of participants in the monthly injection arm and 2% in the bimonthly injection arm discontinued treatment because of injection site pain.
- In the ATLAS-2M trial, <1% of participants in the monthly injection arm and 2% in the bimonthly injection arm had CVF.

BOX 2: Preparation and Administration of Initial and Maintenance Doses of CAB/RPV LA [a]

- Bring the vials [a] of CAB LA and RPV LA to room temperature for at least 15 minutes and for a maximum of 6 hours.
- Prepare 2 syringes [a]. Once CAB/RPV LA has been drawn into the syringes, they must be used within 2 hours.
- For aspiration, use a vial adaptor or general-use sterile 21 gauge × 1½ inch hypodermic needle [b]. Shake the vial vigorously for at least 10 seconds before aspiration.
- For injection, use a general-use sterile 23 gauge × 1½ inch hypodermic needle [b]. Administer the injection within 2 hours of syringe preparation. A patient's build or body mass index may be considered when selecting an appropriate injection needle length.
- Inject into the gluteus medius muscle [c] at a 90° angle, ventrogluteal (preferred) or dorsogluteal (upper-outer quadrant of the buttock), with care that the compound is not injected into a vein.

Notes:

- The same preparation and administration are used for both initial and maintenance doses of CAB/RPV LA. Follow sterile technique at all points while preparing syringes and injecting compounds. Use 3 mL vials/syringes for the initial dose and 2 mL vials/syringes for maintenance doses.
 - The hypodermic needle must be long enough to inject the medication into the muscle mass without penetrating underlying nerves, blood vessels, or bone.
 - Inject CAB LA into the gluteus medius muscle and RPV LA into the contralateral gluteus medius muscle. Injections can be given on opposite sides or on the same side, 2 cm apart.
- For more detail, see instructions for use in the CAB/RPV LA package insert.



← Use this code with your phone's QR code reader to go directly to a mobile-friendly version of the guideline.

■ This ¼-Folded Guide is a companion to the New York State Department of Health AIDS Institute guideline *Use of Injectable CAB/RPV LA as Replacement ART*. The full guideline is available at www.hivguidelines.org.